VRTXVertex Pharmaceuticals Incorporated

VRTX Stock Price, Valuation & Chart | Vertex Pharmaceuticals Incorporated

Compare

$547.65+3.13 (+0.57%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology VRTX intrinsic value VRTX calculated fair value vs price

Overview Financials Dividends Ratios

VRTX Historical price chart

VRTX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization139.00B

PE Ratio28.78

EPS19.03

Trading Volume732.55K

Today's High/Low551.4/545.08

Dividend Yield0.00

52 Week High/Low555.69/374.17

Shares Outstanding253.81M

VRTX Financial Statement

VRTX Analyst ratings

VRTX Analysis & performance metrics

VRTX Company profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets…

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6…

VRTX Management team

Name

Position

Kristen C. Ambrose CPA

Senior Vice President & Chief Accounting Officer

Jonathan Biller J.D.

Executive Vice President & Chief Legal Officer

Reshma Kewalramani FASN, M.D.CEO

Chief Executive Officer, President & Director

Ourania Tatsis Ph.D.

Executive Vice President and Chief Regulatory & Quality Officer

Susie Lisa C.F.A.

Senior Vice President of Investor Relations

Stephanie Franklin

Senior Vice President & Chief Human Resources Officer

David M. Altshuler M.D., Ph.D.

Executive Vice President & Chief Scientific Officer

Nina Devlin

Senior Vice President & Chief Communications Officer

Name

Position

Kristen C. Ambrose CPA

Senior Vice President & Chief Accounting Officer

Jonathan Biller J.D.

Executive Vice President & Chief Legal Officer

Reshma Kewalramani FASN, M.D.CEO

Chief Executive Officer, President & Director

Ourania Tatsis Ph.D.

Executive Vice President and Chief Regulatory & Quality Officer

Susie Lisa C.F.A.

Senior Vice President of Investor Relations

Stephanie Franklin

Senior Vice President & Chief Human Resources Officer

David M. Altshuler M.D., Ph.D.

Executive Vice President & Chief Scientific Officer

Nina Devlin

Senior Vice President & Chief Communications Officer

Management Team

Kristen C. Ambrose CPA

Senior Vice President & Chief Accounting Officer

Jonathan Biller J.D.

Executive Vice President & Chief Legal Officer

Reshma Kewalramani FASN, M.D.CEO

Chief Executive Officer, President & Director

Ourania Tatsis Ph.D.

Executive Vice President and Chief Regulatory & Quality Officer

Susie Lisa C.F.A.

Senior Vice President of Investor Relations

Stephanie Franklin

Senior Vice President & Chief Human Resources Officer

David M. Altshuler M.D., Ph.D.

Executive Vice President & Chief Scientific Officer

Nina Devlin

Senior Vice President & Chief Communications Officer

Management

Kristen C. Ambrose CPA

Senior Vice President & Chief Accounting Officer

Jonathan Biller J.D.

Executive Vice President & Chief Legal Officer

Reshma Kewalramani FASN, M.D.CEO

Chief Executive Officer, President & Director

Ourania Tatsis Ph.D.

Executive Vice President and Chief Regulatory & Quality Officer

Susie Lisa C.F.A.

Senior Vice President of Investor Relations

Stephanie Franklin

Senior Vice President & Chief Human Resources Officer

David M. Altshuler M.D., Ph.D.

Executive Vice President & Chief Scientific Officer

Nina Devlin

Senior Vice President & Chief Communications Officer

Total 8 executives

VRTX Frequently asked questions

What is Vertex Pharmaceuticals Incorporated (VRTX) Stock Price?

Current stock price of Vertex Pharmaceuticals Incorporated (VRTX) stock is $547.65. The stock price is +0.57% higher in the session. The intraday range can be seen from this page. Volume of Vertex Pharmaceuticals Incorporated (VRTX) stock is 732.55K.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Vertex Pharmaceuticals Incorporated (VRTX) stock price going up or down today?

The stock price of Vertex Pharmaceuticals Incorporated (VRTX) can change with earnings, company news, and overall market sentiment. Vertex Pharmaceuticals Incorporated operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Vertex Pharmaceuticals Incorporated stock expensive at its current price?

Whether Vertex Pharmaceuticals Incorporated looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for VRTX on this page is 28.78. EPS on this page is 19.03. Compare those figures with peers and growth expectations before deciding if the current Vertex Pharmaceuticals Incorporated price is justified.

How has the stock price of Vertex Pharmaceuticals Incorporated (VRTX) performed historically?

Historical performance for Vertex Pharmaceuticals Incorporated (VRTX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how VRTX reacted to past earnings and market events.

Should I buy Vertex Pharmaceuticals Incorporated (VRTX) stock, at this price?

Buying Vertex Pharmaceuticals Incorporated (VRTX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.